Phase 2 randomised trial, repurposing Danazol and VBaP in low-risk myelodysplastic syndrome: REPAIR MDS

被引：0

作者：

Raghavan, Manoj ^{[3
]}

Jenkins, Stephen ^{[1
,2
]}

Wintrich, Sophie ^{[4
]}

Drayson, Mark ^{[3
]}

Bunce, Chris ^{[3
]}

Culligan, Dominic ^{[5
]}

Kulasekararaj, Austin ^{[6
,7
]}

Wiseman, Dan ^{[8
,9
]}

Foster, Bethany ^{[1
]}

Dunn, Janet ^{[1
]}

机构：

[1] Univ Warwick, Coventry, W Midlands, England

[2] Dudley Grp NHS Fdn Trust, Dudley, England

[3] Univ Birmingham, Birmingham, W Midlands, England

[4] MDS UK Support Grp, London, England

[5] Aberdeen Royal Infirm, Aberdeen, Scotland

[6] Kings Coll Hosp London, London, England

[7] Kings Coll London, London, England

[8] CRCUK Manchester, Machester, England

[9] Christie NHS Fdn Trust, Machester, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-EP17

引用

页码：153 / 153

页数：1

共 50 条

[41] A MULTICENTRIC PROSPECTIVE PILOT STUDY ON FERROPTOSIS BIOMARKERS IN LOW-RISK MYELODYSPLASTIC SYNDROME
D'avino, C.
Pantaleo, A.
Tsamesidis, I.
Pilo, F.
Reybier, K.
Manca, A.
Greco, M.
Fozza, C.
HAEMATOLOGICA, 2022, 107 : 63 - 64
[42] Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine
Daitoku, Shinya
Aoyagi, Tomomi
Takao, Shinichiro
Tada, Seiya
Kuroiwa, Mika
INTERNAL MEDICINE, 2018, 57 (20) : 2995 - 2999
[43] Treatment of Low-Risk Myelodysplastic Syndrome: Hematopoietic Growth Factors Erythropoietins and Thrombopoietins
Santini, Valeria
SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 295 - 303
[44] Quality of Life in Low-Risk Myelodysplastic Syndrome: A Cross-Sectional Study
Kaygusuz-Atagunduz, Isik
Ozen, Mirac
Firatli-Tuglular, Tulin
Toptas, Tayfur
BLOOD, 2015, 126 (23)
[45] INFERIOR OUTCOME IN LOW-RISK MYELODYSPLASTIC SYNDROME PATIENTS EXHIBITING IRON OVERLOAD
Sumoza, M.
Yellapragada, S.
Roque, W.
Mims, M.
Rivero, G.
LEUKEMIA RESEARCH, 2015, 39 : S138 - S138
[46] Engraftment of Immature Hematopoietic Low Risk Myelodysplastic Syndrome (MDS) Cells in Conjunction with MSCs
Medyouf, H.
Nolte, F.
Mossner, M.
Nowak, V.
Zens, B.
Muedder, K.
Oblaender, J.
St Fey
Klaumuenzer, M.
Fabarius, A.
Riedl, E.
Marx, A.
Roehl, H.
Mueller, N.
Metzgeroth, G.
Huetter, G.
Hofmann, W. K.
Nowak, D.
Trumpp, A.
ANNALS OF HEMATOLOGY, 2013, 92 : S59 - S59
[47] Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial
Gonzalez-Lugo, Jesus D.
Kambhapati, Suman
Yacoub, Abdulraheem
Donnellan, William
Bhagat, Prafulla
Fehn, Karen
Remy, Cassady
Jasra, Sakshi
Kazemi, Mohammad
Mantzaris, Ioannis
Sica, R. Alejandro
Bachier-Rodriguez, Lizamarie
Goldfinger, Mendel
Kornblum, Noah
Gristman, Kira
Braunschweig, Ira
Steidl, Ulrich G.
Will, Britta
Shastri, Aditi
Verma, Amit
BLOOD, 2021, 138
[48] Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higherrisk myelodysplastic syndrome (MDS).
Desikan, Sai Prasad
Montalban-Bravo, Guillermo
Ohanian, Maro
Daver, Naval Guastad
Kadia, Tapan M.
Venugopal, Sangeetha
Chien, Kelly Sharon
Kanagal-Shamanna, Rashmi
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS).
Saba, H
Rosenfeld, C
Issa, JP
DiPersio, J
Raza, A
Klimek, V
Slack, J
de Castro, C
Mettinger, K
Kantarjian, H
BLOOD, 2004, 104 (11) : 23A - 23A
[50] Mesenchymal stromal cells support significant engraftment of low-risk myelodysplastic syndromes (MDS) in a murine xenograft model
Medyouf, H.
Mossner, M.
Nolte, F.
Jann, J. C.
Nowak, V.
Zens, B.
Muedder, K.
Oblaender, J.
Fey, S.
Fabarius, A.
Riedl, E.
Marx, A.
Roehl, H.
Mueller, N.
Metzgeroth, G.
Huetter, G.
Hofmann, W. K.
Trumpp, A.
Nowak, D.
LEUKEMIA RESEARCH, 2013, 37 : S14 - S14

← 1 2 3 4 5 →